We've all heard that criticism of the regime: that it's unduly complicated and difficult to navigate. But anybody who is familiar with patent litigation in the pharmaceutical industry, particularly under the patented medicines notice of compliance regulations, with which some of you are familiar, will find that criticism hard to accept.
We're talking about some of the savviest, most sophisticated, smartest legal entities out there. As I mentioned earlier in French, the regulatory burden that generic drug companies face in trying to get into the domestic market is far in excess of the regulatory steps they have to go through here. It's really a question of will and it's a question of enticement. If you told a generic company that they had to get a man on Mars to be the first with a generic version of a blockbuster drug, they'd have a guy there in six months, not including travel time. So I don't find that objection credible, from my own perspective.
In terms of the actual Apotex example, my understanding is that it got bogged in the voluntary licensing phase. But David knows the facts of that case better than I do, so I'll turn it over to him.